Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the ...

Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in ...

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what ...

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

In addition to Prevent Blindness’s usual free resources, the organization is providing a dedicated webpage, fact sheets, and ...